Pfizer Stakes $43b On Seagen
Pfizer, the pharmaceutical giant, has entered a merger agreement with Seagan Inc., a global biotechnology company, for $43 billion or $229 per share. Seagan discovers, develops and commercialises cancer medicines. The companies expect to complete the merger in late 2023...